title: The physiological response of protease inhibition in dystrophic muscle.
abstract: Duchenne muscular dystrophy (DMD) is caused by the production of a non-functional dystrophin gene product and a failure to accumulate functional dystrophin protein in muscle cells. This leads to membrane instability, loss of Ca(2+) homoeostasis and widespread cellular injury. Associated with these changes are increased protease activities in a variety of proteolytic systems. As such, there have been numerous investigations directed towards determining the therapeutic potential of protease inhibition. In this review, evidence from genetic and/or pharmacological inhibition of proteases as a treatment strategy for DMD is systematically evaluated. Specifically, we review the potential roles of calpain, proteasome, caspase, matrix metalloproteinase and serine protease inhibition as therapeutic approaches for DMD. We conclude that despite early results to the contrary, inhibition of calpain proteases is unlikely to be successful. Conversely, evidence suggests that inhibition of proteasome, matrix metalloproteinases and serine proteases does appear to decrease disease severity. An important caveat to these conclusions, however, is that the fundamental cause of DMD, dystrophin deficiency, is not corrected by this strategy. Hence, this should not be viewed as a cure, but rather, protease inhibitors should be considered for inclusion in a therapeutic cocktail. Physiological Relevance. Selective modulation of protease activity has the potential to profoundly change intracellular physiology resulting in a possible treatment for DMD. However, alteration of protease activities could also lead to worsening of disease progression by promoting the accumulation of substrates in the cell. The balance of benefit and potential damage caused by protease inhibition in human DMD patients is largely unexplored.
authors: Department of Animal Science, Iowa State University, Ames, IA, USA.
authors: K
authors: K
authors: Hollinger
authors: J T
authors: JT
authors: Selsby
mesh_terms: D001343:Autophagy / Q000502:physiology; D006801:Humans; D018482:Muscle, Skeletal / Q000187:drug effects / Q000201:enzymology*; D020388:Muscular Dystrophy, Duchenne / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D011480:Protease Inhibitors / Q000627:therapeutic use*; D057057:Serine Proteases / Q000378:metabolism*
chemical_list: D011480:Protease Inhibitors; D057057:Serine Proteases